';
CLOSE
Substance Use Disorder

0 765

Message from the Office of Mental Health and Substance Abuse Services (OMHSAS):

The Pennsylvania Department of Human Services’ (DHS) Office of Mental Health and Substance Abuse Services (OMHSAS) is issuing the bulletin OMHSAS-25-05 “Behavioral Health Clinic Services Provided Outside of the Clinic,” effective November 12, 2025, following changes to Federal Regulation 42 CFR 440.90(d).

OMHSAS 25-05 announces an amendment to Pennsylvania’s Medicaid State Plan which allows all behavioral health clinics that are enrolled in the Medical Assistance (MA) Program, who deliver services through the fee-for-service and managed care systems, to provide clinically appropriate services outside of the clinic. Behavioral health clinics include psychiatric outpatient clinics, outpatient drug and alcohol clinics, and methadone maintenance clinics.

Furthermore, OMHSAS-25-05 also announces the abrogation of 55 Pa Code §§ 1153.14(6) (relating to noncovered services) and 55 Pa. Code 1223.14(11) (relating to noncovered services) by Act 46 of 2025.

The guidance in OMHSAS-25-05 is separate from any “telehealth only” licensure and guidance that may be in place. The changes discussed in this bulletin also do not apply to the existing Mobile Mental Health Telehealth (MMHT) services.

Questions and comments can be directed to OMHSAS via email. RCPA members can also contact RCPA COO and MH Policy Director Jim Sharp with any questions.

0 221

RCPA is excited to host a membership benefits webinar on Wednesday, January 14, 2026, at 1:00 pm, as an opportunity for members to orient themselves with all that RCPA membership includes. This is not just for new and future members. For current members, there may be benefits associated with our membership that you may not be aware of, including targeted meetings and groups that are held throughout the year.

Registration is required; please register here to attend the webinar. Attendees will have the opportunity to:

  • Virtually meet the dedicated RCPA Policy Staff and RCPA lobbyists;
  • Discuss the 2026 Legislative and Administrative priorities;
  • Preview RCPA divisional committee and subcommittee meetings and what they offer;
  • View the RCPA member-only website;
  • Review exclusive yearly educational and networking events; and
  • Understand the value of the National Council and ANCOR memberships included with RCPA membership.

Visit the RCPA member benefits web page for more information, or contact Tieanna Lloyd for benefit details.

0 510

TrueNorth Wellness Services (TNWS) and its Board of Directors are pleased to announce the appointment of Steven (Steve) J. Schedler, LCSW, CAADC, CCS as its new Chief Executive Officer (CEO), effective January 5, 2026.

With a strong record of leadership in the mental health field, Steve brings a renewed vision for expanding and strengthening our commitment to providing compassionate, high quality behavioral health and wellness services to the communities we serve. Throughout his career, he has demonstrated a deep commitment to expanding access to high quality behavioral health and wellness services, values that align closely with TrueNorth’s intended mission.

We are confident that Steve’s vision and leadership will help TNWS continue to grow and serve our communities with excellence.

Steve replaces Chuck Smith, who has served as the TNWS interim CEO since April 2025.

Professional Background
Steve Schedler comes to TNWS with over 20 years’ experience in the behavioral health field. Since 2020, he has served as the Executive Director of Samaritan Center, where he oversaw clinical and administrative operations.  Prior to that, he served as Executive Director of Naaman Center, a role he led a comprehensive array of addiction treatment services.

These combined leadership experiences, along his roles as a therapist, have equipped Steve with a deep understanding of behavioral health systems, as well as a proven ability to guide diverse teams, implement strategic initiatives and support sustainable service delivery.

Education
Steve holds a Bachelor of Science degree in Psychology from The Pennsylvania State University, a Masters of Social Work degree from Temple University, along with several professional designations.

Personal Background
A native of Franklin County (Mont Alto), PA and a Waynesboro High School graduate, Steve currently lives in Hershey, PA with his wife Amy and two children, Levi and Maddie.

As we begin this new chapter, we are confident that Steve’s leadership and experience will guide TNWS toward continues growth impact. We welcome Steve to TNWS and look forward to the positive energy and direction he will deliver to our team.

0 2296

The Office of Developmental Programs (ODP) has shared this important announcement from the U. S. Food and Drug Administration (FDA).

The FDA is aware that Abbott Diabetes Care has sent all affected customers, distributors, and health care providers a letter regarding an issue with certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors providing incorrect low glucose readings. If undetected, incorrect low glucose readings over an extended period may lead to wrong treatment decisions for people living with diabetes, such as excessive carbohydrate intake or skipping or delaying insulin doses. These decisions may pose serious health risks, including potential injury or death, or other less serious complications.

As of November 14, 2025, Abbott has reported 736 serious injuries and seven deaths associated with this issue.

Affected Product

  • FreeStyle Libre 3 Sensor
    • Model Numbers: 72081-01, 72080-01
    • Unique Device Identifiers (UDI-DI): 00357599818005, 00357599819002
  • FreeStyle Libre 3 Plus Sensor
    • Model Numbers: 78768-01, 78769-01
    • Unique Device Identifiers (UDI-DI): 00357599844011, 00357599843014
  • Download the full list of affected lots

What to Do:

Patients should verify if their sensors are impacted and immediately discontinue use and dispose of the affected sensor(s).

On November 24, 2025, Abbott Diabetes Care sent all affected customers a letter recommending the following actions:

  • For Patients:
    • Determine if your current or unused sensor(s) are affected by visiting FreeStyle Check and selecting “CONFIRM SENSOR SERIAL NUMBER.” You will need to locate your sensor serial number to determine if your sensor is affected.
      • If you are wearing a FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensor, you can find the serial number in the app or reader. The serial number can also be found on the label on the bottom of the sensor applicator or carton. (If you are using a sensor with a connected insulin delivery device, please refer to the connected insulin delivery device user manual on how to locate the sensor serial number.)
    • If you are currently wearing or have a FreeStyle Libre 3 or FreeStyle Libre 3 Plus sensor that has been confirmed as potentially affected on FreeStyle Check or by a customer service representative, immediately discontinue use and dispose of the affected sensor(s).
    • You can request a replacement for any potentially affected sensor(s) on FreeStyle Check. Select “CONFIRM SENSOR SERIAL NUMBER” and enter a valid serial number. If your sensor is potentially impacted, you will be instructed to enter your contact information so a replacement product can be sent to you at no cost.
    • Use a blood glucose meter or the built-in meter in your FreeStyle Libre 3 Reader to make treatment decisions when your sensor readings don’t match your symptoms or expectations.

Visit the FDA’s website for additional information and instructions on how to locate the Sensor’s Serial Number.

0 6166

Message from the Center for Connected Health Policy (CCHP):

On November 10, 2025, the U.S. Drug Enforcement Administration (DEA) posted a fourth temporary extension of the COVID-19 telemedicine flexibilities for prescribing controlled substances. These flexibilities were set to expire at the end of the year. Although the DEA has not yet released the full text of the extension — including how long it will last. At this point, the final rule is still pending regulatory review. Historically, extensions have added a year of continued flexibility, though this extension could be shorter. For context, the previous extension, issued in November 2024, extended the telemedicine allowances through December 31, 2025. Until the fourth extension rule is approved and the complete text published, the duration and any potential policy adjustments remain unknown.

As background, permanent federal law under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 largely prohibits the prescribing of controlled substances without an initial in-person examination. While the statute outlines several exceptions under the defined “practice of telemedicine,” these apply primarily when a patient is located in a hospital or clinic or in the presence of another practitioner. As a result, these exceptions do not cover the routine model of telehealth widely used today, in which the patient (and sometimes the provider) participate from home settings. Importantly, the in-person requirement under the Ryan Haight Act applies only to the initial visit, and the DEA has never required subsequent in-person encounters. While the full details are not yet available, it is likely that the forthcoming temporary extension will mirror previous ones by continuing to suspend the initial in-person visit requirement for the period of the extension.

It is important to note that these DEA extensions affect only federally-controlled substance prescribing rules. States maintain their own requirements, which may include stricter requirements for in-person visits prior to the prescribing of controlled substances. Please check the Online Prescribing category of CCHP’s Policy Finder to reference state specific requirements.

Additionally, the DEA’s in-person prescribing requirement is separate from Medicare’s policy requiring an in-person visit within six months prior to an initial telehealth mental health service and annually thereafter. That Medicare mental health requirement — often confused with the DEA’s prescribing standard — is tied to Medicare reimbursement rules and applies only to Medicare beneficiaries and providers seeking reimbursement for mental health services through Medicare if their situations do not meet certain exceptions, not to all patients. Additionally, this Medicare in-person visit requirement is currently waived until January 30, 2026 (as passed in the most recent government funding bill), whereas the DEA’s in-person requirement, which is the topic of this particular newsletter and the new fourth extension rule, governs all practitioners prescribing controlled substances nationwide, regardless of payer.

If RCPA members have any questions, please contact RCPA COO and Mental Health Policy Director Jim Sharp.

0 360

RCPA has formalized its opposition to SB 716 in a brief position paper. Senator Laughlin’s SB 716 would amend Pennsylvania’s Mental Health Procedures Act (MHPA) by defining substance use disorder (SUD) as a mental illness, thereby subjecting those with an SUD to the same procedures outlined in MHPA, including an involuntary commitment to a 120-hour hold in a psychiatric hospital, which is commonly referred to as a 302 (Section 302 of MHPA).

RCPA determined its position after months of discussion and analysis, including:

  • Written input from the entire RCPA SUD treatment provider membership;
  • Extensive conversations and meetings with RCPA members, including SUD and mental health treatment providers, the SUD Steering Committee, and governmental entities;
  • Multiple meetings with staff from key legislators’ offices, including Sen. Laughlin;
  • Multiple meetings with the Shapiro administration; and
  • A review of published research detailing experiences other states have had with involuntary commitment for SUD.

RCPA has offered to work with the legislature and Sen. Laughlin to implement alternative strategies that are proven effective in reducing overdoses and connecting those with SUD to treatment.

0 532

Early this year, the FASD Respect Act was introduced in the Senate to authorize and modify programs administered by the Department of Health and Human Services to address fetal alcohol spectrum disorders (FASD), and became a provision of the SUPPORT for Patients and Communities Reauthorization Act. The bill sought to establish FASD Centers for Excellence to support FASD prevention through screenings, public awareness, and trainings at a local and state level. In September, Congress passed the SUPPORT Act, and last week the President signed it into law, which officially authorizes the FASD Respect Act.

The legislation will allow the US Department of Health and Human Services to promote and fund FASD education and awareness, as well as the promotion of FASD resources. Beyond funding and program expansion, the FASD Respect Act will task the federal government with addressing FASD through a realigned perspective that supports individuals and families and respects their lived experience.

Please contact Emma Sharp with any questions.

123...143Next Page 1 of 143
© 2021 - Rehabilitation & Community Providers Association